Latest:
Dr. Stenzl on Future Research With Enzalutamide in Prostate Cancer
Arnulf Stenzl, MD, discusses future research efforts with enzalutamide in prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Xiaojia Wang, MD
Xiaojia Wang, MD, is an oncologist in the Department of Breast Medical Oncology at the Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital and a key researcher at the Institute of Cancer and Basic Medicine (IBMC) at the Chinese Academy of Sciences in Hangzhou, China.
Latest:
Dr Wang on Updated Efficacy and Safety Data With First-Line Ivonescimab Plus Chemotherapy in TNBC
Xiaojia Wang, MD, shares responses achieved with the combination of ivonescimab plus chemotherapy in locally advanced unresectable or metastatic TNBC.
Arutha Kulasinghe, PhD
Latest:
Dr Kulasinghe on a Study Profiling the NSCLC Tumor Microenvironment
Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.
Alissa J. Cooper, MD
Latest:
Final Thoughts and Clinical Pearls for Treating SCLC
Panelists discuss how the next 3 to 5 years will likely see T-cell engagers moving into earlier treatment lines, potential ADCs replacing chemotherapy in first-line therapy, and the critical need for better biomarker testing to optimize treatment sequencing and patient selection in an increasingly complex therapeutic landscape.
Beth N. McLellan, MD
Latest:
Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis
Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.
Millie Das, MD
Millie Das, MD, is a clinical professor of medicine – oncology in the Department of Medicine at Stanford University; a member of the Stanford Cancer Institute; and chief of Oncology at the VA Palo Alto Health Care System
Latest:
Dr Das on Updates to the Standard First-Line Treatment Paradigm for ES-SCLC
Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.
Judith Karp, MD
Latest:
Women in Oncology: Leukemia Therapies in Humans, for Humans
Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..